PO.PS01.09 · 人群科学

多发性骨髓瘤中的情绪功能与NR3C1和FKBP5表达

Emotional functioning and NR3C1 and FKBP5 expression in multiple myeloma

海报缩略图:多发性骨髓瘤中的情绪功能与NR3C1和FKBP5表达
编号 7609 展板 29 时间 4/22 09:00–12:00 区域 Section 35 主讲 Mark Fiala, PhD
分会场 Risk Prediction Modeling, Screening, Early Detection, and Preneoplastic and Tumor Markers
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Mark Aaron Fiala1, Steven Cole2, Judith E. Carroll2

1Washington Univeristy School of Medicine, St. Louis, MO,2UCLA - University of California Los Angeles, Los Angeles, CA

摘要 Abstract

中文摘要
引言:情绪困扰在癌症诊断后很常见,并且对某些癌症而言还与更差的预后相关。然而,情绪困扰对多发性骨髓瘤(MM)患者的影响仍相对研究不足。方法:本研究利用了CoMMpass(IA22)的数据,这是一项针对1000余名患者的纵向研究,这些患者提供了生物样本、临床数据和患者报告结局(PROs)。在本分析中,我们旨在确定MM诊断时基于患者报告和/或生物标志物的情绪困扰指标是否与患者结局相关。患者在诊断时完成EORTC QLQ-C30量表。计算情绪功能子量表,评分范围为0-100,分数越低表示困扰越高。CoMMpass缺乏皮质醇和细胞因子等常见困扰生物标志物的数据。因此,我们使用了两个在应激反应中发挥重要作用、且在有情绪困扰人群中失调的基因NR3C1和FKBP5的mRNA表达(对CD138富集的MM细胞进行mRNA-seq)。 分析:将患者报告的情绪功能以及NR3C1和FKBP5表达分为四分位数。情绪功能处于最低四分位数的患者被归类为存在情绪困扰。采用ANOVA和x²检验评估情绪功能、应激生物标志物与相关临床因素之间的关联。采用Cox回归评估与无进展生存期和总生存期的关联,并对患者年龄、性别、种族和分期(国际分期系统[ISS])进行校正。结果:572例患者具有基线PROs和mRNA-seq数据。中位年龄为64岁[IQR 57-71],59%为男性,78%为白人,15%为黑人,7%为其他种族。中位情绪功能评分为75[IQR 58.3-91.7]。患者报告的情绪功能与较高的FKBP5表达之间存在关联(p = 0.043),但与NR3C1无关联(p = 0.932),尽管FKBP5与NR3C1之间存在强正相关(p < 0.001)。情绪功能还与年龄(p = 0.023)、性别(p = 0.006)和种族(p = 0.003)相关,但与ISS分期无关(p = 0.980)。在多变量模型中,情绪困扰和FKBP5表达均与预后独立相关。有情绪困扰的患者进展风险增加39%(aHR 1.39;95% CI 1.07-1.79;p = 0.012),但情绪困扰与总生存期无关。FKBP5表达处于最高四分位数的患者进展风险增加53%(aHR 1.53;95% CI 1.16-2.03;p = 0.003),死亡风险增加64%(aHR 1.64;95% CI 1.14-2.36;p = 0.007)。 结论:情绪功能和FKBP5表达均与MM预后独立相关。在进一步分析中,我们旨在探索这些关联背后的机制,并评估潜在的干预措施以减轻对MM结局的不利影响。
查看英文原文 English abstract
Introduction: Emotional distress is common following a cancer diagnosis, and for some cancers it has also been associated with worse outcomes. However, the impact of emotional distress in patients with multiple myeloma (MM) remains relatively understudied. Methods: This study utilized data from CoMMpass (IA22), a longitudinal study of over 1000 patients who provided biospecimens, clinical data, patient reported outcomes (PROs). In this analysis, we aimed to determine if patient-reported and/or biomarker-based indicators of emotional distress at MM diagnosis were associated with patient outcomes. Patients completed the EORTC QLQ-C30 at diagnosis. The emotional functioning subscale was calculated, with scores ranging 0-100 and lower scores indicating higher distress. CoMMpass lacks data on common biomarkers for distress such as cortisol and cytokines. Therefore, we used mRNA expression (mRNA-seq on CD138-enriched MM cells) of two genes that play an important role in stress response and are dysregulated in people with emotional distress, NR3C1 and FKBP5. Analysis: Patient reported emotional functioning and NR3C1 and FKBP5 expression were classified into quartiles. Patients in the lowest quartile of emotional functioning were classified as having emotional distress. Associations between emotional functioning, stress biomarkers, and relevant clinical factors were assessed using ANOVA and x 2 . Associations with progression-free and overall survival were assessed using Cox Regression and adjusted for patient age, sex, race, and stage (International Staging System [ISS]). Results: 572 patients had baseline PROs and mRNA-seq data. The median age was 64 [IQR 57-71], 59% were male, 78% were White, 15% were Black, and 7% were another race. The median emotional functioning score was 75 [IQR 58.3-91.7]. There was an association between patient reported emotional functioning and higher FKBP5 expression (p = 0.043), but not NR3C1 (p = 0.932), despite a strong positive association between FKBP5 and NR3C1 (p < 0.001). Emotional functioning was also associated with age (p = 0.023), sex (p = 0.006), and race (p = 0.003), but not ISS stage (p = 0.980). In multivariable models, both emotional distress and FKBP5 expression were independently associated with prognosis. Patients with emotional distress had a 39% increase in hazard for progression (aHR 1.39; 95% CI 1.07-1.79; p = 0.012), but emotional distress was not associated with overall survival. Patients in the highest quartile of FKBP5 expression had a 53% increase in hazard for progression (aHR 1.53; 95% CI 1.16-2.03; p = 0.003) and 64% increase in hazard for death (aHR 1.64; 95% CI 1.14-2.36; p = 0.007). Conclusion: Emotional Functioning and FKBP5 expression are both independently associated with MM prognosis. In further analyses, we aim explore the mechanisms underlying these associations and to evaluate potential interventions to mitigate the adverse effects on MM outcomes.
利益披露 Disclosure
M. A. Fiala, Bristol-Myers Squibb ). S. Cole, None.

← 返回 AACR 2026 检索